Risk Factors for Bleeding during Treatment of Acute Venous Thromboembolism

Summary

Objective: Identification of risk factors for bleeding and prospective evaluation of two bleeding risk scores in the treatment of acute venous thromboembolism.

Design: Secondary analysis of a prospective, randomized, assessor-blind, multicenter clinical trial.

Setting: One university and 2 regional teaching hospitals.

Patients: 188 patients treated with heparin or danaparoid for acute venous thromboembolism.

Measurements: The presenting clinical features, the doses of the drugs, and the anticoagulant responses were analyzed using univariate and multivariate logistic regression analysis in order to evaluate prognostic factors for bleeding. In addition, the recently developed Utrecht bleeding risk score and Landefeld bleeding risk index were evaluated prospectively.

Results: Major bleeding occurred in 4 patients (2.1%) and minor bleeding in 101 patients (53.7%). For all (major and minor combined) bleeding, body surface area ≤2 m2 (odds ratio 2.3, 95% Cl 1.2-4.4; p = 0.01), and malignancy (odds ratio 2.4, 95% Cl 1.1-4.9; p = 0.02) were confirmed to be independent risk factors. An increased treatment-related risk of bleeding was observed in patients treated with high doses of heparin, independent of the concomitant activated partial thromboplastin time ratios. Both bleeding risk scores had low diagnostic value for bleeding in this sample of mainly minor bleeders.

Conclusions: A small body surface area and malignancy were associated with a higher frequency of bleeding. The bleeding risk scores merely offer the clinician a general estimation of the risk of bleeding. In patients with a small body surface area or in patients with malignancy, it may be of interest to study whether limited dose reduction of the anticoagulant drug may cause less bleeding without affecting efficacy.

• References

• 1 Hirsh J. Heparin. N Engl J Med 1991; 324: 1565-1574
• 2 Brandjes DPM, Heijboer H, Biiller HR, De Rijk M, Jagt H, ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992; 327: 1485-1489
• 3 Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction and prevention. Am J Med 1993; 95: 315-328
• 4 Salzman EW, Deykin D, Shapiro RM, Rosenberg R. Management of heparin therapy. Controlled prospective trial. N Engl J Med 1975; 292: 1046-1050
• 5 Walker AM, Jick H. Predictors of bleeding during heparin therapy. JAMA 1980; 244: 1209-1212
• 6 Petiti DB, Strom BL, Melmon KL. Duration of warfarin anticoagulant therapy and the probabilities of recurrent thromboembolism and hemorrhage. Am J Med 1986; 81: 255-259
• 7 Petiti DB, Strom BL, Melmon KL. Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin. J Clin Epidemiol 1989; 42: 759-764
• 8 Hull RD, Raskob GE, Rosenbloom D, Panju AA, Brill-Edwards P, Ginsberg JS. et al Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990; 322: 1260-1264
• 9 Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 1987; 82: 703-713
• 10 Landefeld CS, McGuire III E, Rosenblatt MW. A bleeding risk index for estimating the probability of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 1990; 89: 569-578
• 11 Hommes DW, Bura A, Mazzolai L, Biiller HR, ten Cate JW. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. Ann Intern Med 1992; 116: 279-284
• 12 Albada J, Nieuwenhuis HK, Sixma JJ. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study. Circulation 1989; 80: 935-940
• 13 Duroux P. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicentre study. Thromb Haemost 1991; 65: 251-256
• 14 Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG. et al Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-982
• 15 Prandoni P, Lensing AWA, Biiller HR, Carter M, Cogo A, Vigo M. et al Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339: 441-445
• 16 Salzman EW. Low-molecular-weight heparin and other new antithrombotic drugs. N Engl J Med 1992; 326: 1017-1019
• 17 Holmer E, Mattsson C, Nilsson S. Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits. Thromb Res 1982; 25: 475-485
• 18 Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982; 59: 1239-1245
• 19 Salzman EW. Low-molecular-weight heparin: is small beautiful?. N Engl J Med 1986; 315: 957-959
• 20 Verstraete M. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparin. Drugs 1990; 40: 498-530
• 21 Boneu B, Buchanan MR, Cade JF, van Ryn J, Femandze FF, Ofosu FA. et al Effects of heparin, its low molecular weight fractions and other glycos-aminoglycans on thrombus growth in vivo. Thromb Res 1985; 40: 81-89
• 22 Levine MN, Hirsh J, Gent M, Turpie AG, Leclerc J, Powers PJ. et al Prevention of deep vein thrombosis after elective hip surgery: a randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med 1991; 114: 545-551
• 23 Meuleman DG. Orgaran (Org 10172): its pharmacological profile in experimental models. Haemostasis 1992; 22: 58-65
• 24 Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991; 78: 2337-2343
• 25 de Valk HW, Banga JD, Wester JPJ, Brouwer CB, van Hessen MWJ, Meuwissen OJATh. et al Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial. Ann Intern Med 1995; 123: 1-9
• 26 Mosteller RD. Simplified calculation of body-surface area. N Engl J Med 1987; 317: 1098
• 27 Landefeld CS, Anderson PA, Goodnough LT, Moir TW, Horn DL, Rosenblatt MW. et al The bleeding severity index: validation and comparison to other methods for classifying bleeding complications of medical therapy. J Clin Epidemiol 1989; 42: 711-718
• 28 Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36
• 29 Hanley A, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839-843
• 30 SAS/STAT user‘s guide, version 6. 4th ed Cary, NC: SAS Institute Inc; 1990
• 31 Egret Statistical Package Manual. Seattle, Washington: Statistics and Epidemiology Research Corporation; 1990
• 32 Landefeld CS, Anderson PA. Guideline-based consultation to prevent anticoagulant-related bleeding. A randomized, controlled trial in a teaching hospital. Ann Intern Med 1992; 116: 829-837